KANEKA
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) opened its Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido for the purpose of portfolio transformation and business expansion and held the opening ceremony on August 26. The Tomatoh Manufacturing Site is the seventh domestic business location*1 for the company and the first new one in 54 years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829240050/en/
Tomatoh Manufacturing Site (Photo: Business Wire)
The medical device plant*2 completed at Tomatoh Manufacturing Site will produce adsorption type blood purification devices "Rheocarna™" and adsorption type plasma purification devices "Liposorber™". The number of patients with arteriosclerosis obliterans (ASO)*3, which these medical devices are intended to treat, is on the rise worldwide, along with increases in diabetes, chronic renal failure, and other conditions. By securing the supply base through the new plant, we will dramatically expand our medical business to meet global demand.
The plant has achieved full automation of its production lines as a "smart factory" utilizing robot technology and plans to realize a "zero energy factory" that will reduce the primary energy consumption of the factory building to zero by using our photovoltaic modules, thereby promoting sustainable manufacturing.
In the future, Tomatoh Manufacturing Site will be actively utilized as a new production base for each business, as well as for further expansion of the medical business.
Based on our mission of "KANEKA thinks 'Wellness First'.", we will realize a world where advanced medical care is accessible to everyone and where science contributes to the innovation of the global environment and our daily lives. From Tomakomai, "Kaneka, the Dream Factory" will make this vision a reality.
Participants at the opening ceremony (From the left):
Yoshiro Aikawa, President of Taisei Corporation
Jun Kimura, Deputy Mayor of Tomakomai-city
Naomichi Suzuki, Governor of Hokkaido
Kimikazu Sugawara, Chairman of Kaneka Corporation
Kazuhiko Fujii, President of Kaneka Corporation
Shigenobu Sano, Senior Executive Director of Tomatoh Co., Ltd.
*1. Domestic business locations: Takasago Manufacturing Site, Osaka Manufacturing Site, Shiga Manufacturing Site, Kashima Manufacturing Site, Tomatoh Manufacturing Site, Tokyo Head Office, Osaka Head Office
*2. News Release January 23, 2022
Kaneka to Construct New Medical Device Plant in Hokkaido - Roughly 10 billion yen investment aimed at expanding global business -
https://www.kaneka.co.jp/en/topics/news/2022/ennr2201241.html
*3. A disease that causes arteriosclerosis where stenosis and occlusion of lower limbs artery occurred, leading to impaired blood flow (ischemia). In the early stages, it causes coldness, numbness, and gait disturbance. When the disease progresses to critical limb ischemia with pain and ulceration, the risk of leg amputation and death increases.
About Tomatoh Manufacturing Site
Company Name: Kaneka Corporation Tomatoh Manufacturing Site
Completed: August 26, 2024
Location: 6-253 Kashiwabara, Tomakomai-city, Hokkaido
Business Description: Production of medical devices
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829240050/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Intelecy announces Anna Olsson’s promotion to Chief Operating Officer13.9.2024 16:40:00 CEST | Press release
Intelecy, a leading Norwegian industrial AI company, is excited to announce the promotion of Anna Olsson from Chief Commercial Officer (CCO) to Chief Operating Officer (COO). This move comes as the company accelerates its global expansion, following a year of remarkable growth and successful project deliveries across multiple countries. Anna Olsson, who joined Intelecy with over 20 years of experience in the software industry, has been instrumental in driving the company’s commercial strategy and internationalization. With a robust background in industrial AI and experience from global roles, including her time at Cognite and Microsoft, Olsson’s leadership will now focus on optimizing operations to meet Intelecy’s growing global demand and supporting its continued innovation in AI-driven process optimization and energy management. "I've witnessed the industrial sector’s eagerness to embrace AI for optimizing production, streamlining processes, and driving sustainability. Yet, many stru
Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa13.9.2024 11:00:00 CEST | Press release
Inhalation of colistimethate sodium via the I-neb® Adaptive Aerosol Delivery System (CMS I-neb) significantly reduced pulmonary exacerbations and improved quality of life in non-cystic fibrosis bronchiectasis (NCFB) patients colonized with P. aeruginosa Both trials showed that CMS I-neb was generally well tolerated, with no major safety concerns, and bronchospasm occurred in fewer than 5% of patients Zambon is continuing to work with regulatory authorities with the goal of making colistimethate sodium delivered via a customized inhalation device available to patients with bronchiectasis and P. aeruginosa chronic infection Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, today announced the online publication of its Phase 3 PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicinejournal. The PROMIS studies assessed the efficacy and safety of inhaled colistimethate sodium administere
Intelsat Signs Hybrid Media Deal Distributing Hearst Networks EMEA Content13.9.2024 09:00:00 CEST | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks, successfully launched a hybrid television content distribution service to deliver Hearst Networks EMEA (formerly known as A+E Networks EMEA) channels to hundreds of points across Europe thanks to its seamless satellite-terrestrial connection. “Growing global media customers like Hearst Networks EMEA want to work with a single operator that can provide seamless connections from satellite to ground-based Internet Protocol distribution networks,” said Rhys Morgan, regional vice president, EMEA, Media and Networks. “Intelsat has visibility across the full distribution network, even when it spans multiple technologies and can enable customers to reach more end users.” In order to reach a wide group of viewers, content providers typically use multiple distribution mediums such as direct-to-home (DTH), cable and IPTV. Hearst Networks EMEA needed to maximize the reach of its flagship channels, The H
NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services13.9.2024 08:30:00 CEST | Press release
Under a multi-year contract, the Luxembourg-based satellite operator SES will deliver secure and resilient high-performance connectivity for NATO member governments The NATO Support and Procurement Agency (NSPA) has awarded SES a contract to deliver secure high-performance low-latency satellite services via its medium earth orbit (MEO) constellation, enabling global missions for NATO member government organisations, agencies and military. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910404747/en/ NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services (Photo: Business Wire) The MEO Global Services (MGS) award represents a three-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at USD 200M, with two one-year options. This is the first award under the Global Commercially Contracted Satellite Communications Support Partnership (GCC SATCOM SP) established by the U.
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types13.9.2024 08:00:00 CEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC). “Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom